Skip to main content
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
December 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
ESMO 2023 - Small Cell Lung Cancer
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
Subscribe
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
December 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
ESMO 2023 - Small Cell Lung Cancer
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
Payers' Guide
Drug Updates
,
FDA Approvals
,
Payers' Guide
Revlimid (Lenalidomide) Now FDA Approved as First-Line Therapy for Patients with Multiple Myeloma
Read More
Drug Updates
,
FDA Approvals
,
Payers' Guide
Tresiba (Insulin Degludec Injection) and Ryzodeg 70/30 (Insulin Degludec and Insulin Aspart Injection): Two New Insulin Analogs for Glycemic Control in Diabetes Mellitus
Read More
Drug Updates
,
FDA Approvals
,
Payers' Guide
Zarxio (Filgrastim-sndz): First Biosimilar Approved in the United States
Read More
Drug Updates
,
FDA Approvals
,
Payers' Guide
Competition Heats Up in Rheumatoid Arthritis and Other Autoimmune Conditions
Read More
Drug Updates
,
FDA Approvals
,
Payers' Guide
Empliciti (Elotuzumab): First SLAMF7 Antibody Therapy Approved for the Treatment of Patients with Previously Treated Multiple Myeloma
Read More
FDA Approvals
,
Payers' Guide
The Sixth Annual Payers’ Guide to New FDA Approvals
Read More
Payers' Guide
New FDA Drug Approvals Hit an 18-Year High in 2014
Read More
Drug Updates
,
Payers' Guide
FDA Approvals of Brand-Name Prescription Drugs in 2014
Read More
Drug Updates
,
Payers' Guide
Afrezza (Insulin Human) Inhalation Powder Approved for the Treatment of Patients with Type 1 or Type 2 Diabetes
Read More
Drug Updates
,
Payers' Guide
Akynzeo (Netupitant and Palonosetron), a Dual-Acting Oral Agent, Approved by the FDA for the Prevention of Chemotherapy-Induced Nausea and Vomiting
Read More
8
9
10
11
12
13
14
Page 11 of 19
Results 101 - 110 of 185